Ivana JD - Vigil Neuroscience CEO President

VIGL Stock  USD 2.47  0.17  7.39%   

CEO

Ivana JD is CEO President of Vigil Neuroscience
Age 57
Address 100 Forge Road, Watertown, MA, United States, 02472
Phone857 254 4445
Webhttps://www.vigilneuro.com

Vigil Neuroscience Management Efficiency

The company has return on total asset (ROA) of (0.3966) % which means that it has lost $0.3966 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7012) %, meaning that it created substantial loss on money invested by shareholders. Vigil Neuroscience's management efficiency ratios could be used to measure how well Vigil Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.62. The value of Return On Capital Employed is expected to slide to -0.72. At this time, Vigil Neuroscience's Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 19.9 M this year, although the value of Other Current Assets will most likely fall to about 2.4 M.
Vigil Neuroscience currently holds 13.85 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Vigil Neuroscience has a current ratio of 20.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vigil Neuroscience's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 2 records

CEO Age

BAO BChEliem Therapeutics
48
Samuel MBAEnliven Therapeutics
38
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc. Vigil Neuroscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people. Vigil Neuroscience (VIGL) is traded on NASDAQ Exchange in USA. It is located in 100 Forge Road, Watertown, MA, United States, 02472 and employs 64 people. Vigil Neuroscience is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Vigil Neuroscience Leadership Team

Elected by the shareholders, the Vigil Neuroscience's board of directors comprises two types of representatives: Vigil Neuroscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vigil. The board's role is to monitor Vigil Neuroscience's management team and ensure that shareholders' interests are well served. Vigil Neuroscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vigil Neuroscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Chief Officer
Spyridon MD, Chief Officer
Weeteck Yeo, Senior Operations
Jessica PMP, Senior Management
Mr DABT, Senior Development
Christopher JD, General Secretary
Ivana JD, CEO President
Park CPA, Accounting Manager
Jennifer CPA, Chief Officer
Sharon Morani, Director Operations
Kelly Neelon, Vice Operations
M MBA, VP Development
Charles Maggs, Head FPA
Eric Brophy, Senior Technology
Sarah Carmody, VP Communications
David Gray, Chief Officer
Leah Gibson, Vice Communications
Christian Mirescu, Senior Neuroimmunology

Vigil Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vigil Neuroscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Vigil Neuroscience is a strong investment it is important to analyze Vigil Neuroscience's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vigil Neuroscience's future performance. For an informed investment choice regarding Vigil Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.07)
Return On Assets
(0.40)
Return On Equity
(0.70)
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.